Dr. Campisi has been at the forefront of studying cellular senescence for decades, revealing the mysteries of these not-exactly-dead cells and their role in many diseases of aging. In this episode, she joins her colleague Gordon to discuss the characteristics and function of senescent cells, as well as promising interventions on the horizon. Judy also describes how to get lucky in science by being prepared to see the unexpected.
DISCLOSURE: Longevity. Technology (a brand of First Longevity Limited) has been contracted by the company featured in this article to support its current funding round. Qualifying investors can find out more via the Longevity. Technology investment portal.
MedTech start-up Occuity has received a £343,000 Innovate UK Biomedical Catalyst (BMC) Award to fund the next stage of the development of its innovative AGE reader: an optical medical device that will enable non-invasive screening of diabetes in non-clinical settings such as opticians and pharmacies.
Biomedical Catalyst is the flagship Innovate UK grant funding competition for supporting UK health & life sciences SMEs. It supports the development of innovative solutions to health and healthcare challenges by providing financial support to accelerate the route to commercialisation.
Magnetic fields are all around us. They exist whenever there is electric current and have been used in various aspects of medicine for decades. Today, magnetic fields are used in applications including magnetic resonance imaging (MRI), bone fracture repair, wound healing and pain reduction.
Taking things a step further, US startup EMulate Therapeutics has developed a unique magnetic field technology that has been shown to replicate the effect of drugs in humans and animal models – all without the presence of chemicals. Having spun-out companies in cancer, pain management and beyond, the company is seeking partners for longevity applications of its technology.
Longevity. Technology: The concept behind EMulate’s approach is mind-boggling. The company “records” the electromagnetic signature of specific molecules and is then able to use those recordings to effect changes in cellular behaviour, without using chemicals. In its most advanced programme, EMulate’s technology has completed feasibility clinical trials for adults and children with terminal brain cancer, using a recording derived from chemotherapy drug paclitaxel. We caught up with EMulate’s CEO Chris Rivera to find out more.
Neuralink’s invasive brain implant vs phantom neuro’s minimally invasive muscle implant. Deep dive on brain computer interfaces, Phantom Neuro, and the future of repairing missing functions.
Connor glass.
Phantom is creating a human-machine interfacing system for lifelike control of technology. We are currently hiring skilled and forward-thinking electrical, mechanical, UI, AR/VR, and Ai/ML engineers. Looking to get in touch with us? Send us an email at [email protected].
Phantom Neuro.
Phantom is a neurotechnology company, spun out of the lab at The Johns Hopkins University School of Medicine, that is enabling lifelike control of robotic orthopedic technologies, such as prosthetic limbs and exoskeletons. Phantom’s solution, the Phantom X, consists of low-risk implantable sensors, AI, and enabling software. By providing superior control of robotic orthopedic mechanisms, the Phantom X will drastically improve the lives of individuals with limb difference who have yet to see a tangible improvement in quality of life despite significant advancements in the field of robotics.
Links:
[email protected].
https://www.linkedin.com/in/connor-glass-md-010124141/
https://www.linkedin.com/company/phantomneuro/
PODCAST INFO:
The Learning With Lowell show is a series for the everyday mammal. In this show we’ll learn about leadership, science, and people building their change into the world. The goal is to dig deeply into people who most of us wouldn’t normally ever get to hear. The Host of the show – Lowell Thompson-is a lifelong autodidact, serial problem solver, and founder of startups.
LINKS
Youtube: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q
Youtube clips: https://www.youtube.com/channel/UC-B5x371AzTGgK-_q3U_KfA
Linkedin: https://www.linkedin.com/in/lowell-thompson-2227b074
Twitter: https://twitter.com/LWThompson5
Website: https://www.learningwithlowell.com/
Podcast email: [email protected].
Timestamps.
Evidence-Based And Actionable Health, Wellness And Longevity Solutions — Dr. Renee DeHaan, Ph.D. — VP, Science & AI, InsideTracker
Dr. Renée Deehan, Ph.D. is the VP of Science & Artificial Intelligence at InsideTracker (https://www.insidetracker.com/), and leads a science team that builds and mines the world’s largest data set of blood, DNA, fitness tracking and phenotypic data from healthy people, creating evidence-based solutions that are simple, clear, and actionable.
Dr. Deehan has spent her career working in the precision medicine and personalized nutrition domains, previously serving as the VP of Computational Biology & Translational Informatics at QuartzBio and as the VP of Biology and Bioinformatics at PatientsLikeMe, the world’s largest integrated community, health management, and real-world data platform.
At PatientsLikeMe, Dr. Deehan was responsible for data and knowledge engineering, AI/machine-learning, and translational biology functions that drove infrastructure and consumer & business product development. She was also the Principal Investigator for the DigitalMe Ignite program, which collected longitudinal blood and patient-generated health data from over 5,000 at-home site visits from over 2,000 participants and was able to generate over 2 Million data points from the DigitalMe program.
Dr. Deehan also designed and cross-functionally implemented the first generation of an “advanced research platform”, capable of integrating survey and omics data for biomarker analysis, including ensemble-based machine-learning pipelines. Additionally, they developed an outsourced pipeline to support their wet-lab omics needs (DNA/RNAseq, proteomics, immune sequencing/antibody repertoire analysis, metabolomics, methylomics).
Metformin has been proposed as an “anti-aging drug,” and a major clinical trial is about to get underway to test the idea.
New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new treatments for glaucoma patients.
The study was published today in Aging Cell. Along with her colleagues, Dorota Skowronska‐Krawczyk, Ph.D., assistant professor in the Departments of Physiology & Biophysics and Ophthalmology and the faculty of the Center for Translational Vision Research at the UCI School of Medicine, describes the transcriptional and epigenetic changes happening in aging retina.
The team shows how stress, such as intraocular pressure (IOP) elevation in the eye, causes retinal tissue to undergo epigenetic and transcriptional changes similar to natural aging. And, how in young retinal tissue, repetitive stress induces features of accelerated aging including the accelerated epigenetic age.
Fasting database:
Recreates the immune system;…Prolonged fasting forces the body to use stores of glucose, fat and ketones, but it also breaks down a significant portion of white blood cells. Longo likens the effect to lightening a plane of excess cargo. During each cycle of fasting, this depletion of white blood cells induces changes that trigger stem cell-based regeneration of new immune system cells. In particular, prolonged fasting reduced the enzyme PKA, an effect previously discovered by the Longo team to extend longevity in simple organisms and which has been linked in other research to the regulation of stem cell self-renewal and pluripotency — that is, the potential for one cell to develop into many different cell types. Prolonged fasting also lowered levels of IGF-1, a growth-factor hormone that Longo and others have linked to aging, tumor progression and cancer risk.
Recreates the immune system (page loads slow)
…
Results in mice are first evidence of natural intervention triggering stem cell-dependent regeneration of organ or system.
The company will also expend an aging Falcon 9 booster during a mission for the first time.
SpaceX aims to perform two Falcon 9 rocket launches only six hours apart after a mission scheduled for Nov. 21 was delayed, a report from Teslarati reveals.
A record-breaking year for SpaceX.
SpaceX / Flickr.
Though the weather conditions at Cape Canaveral may scupper the attempts, the missions are another indicator of SpaceX’s impressive schedule this year, which has broken records and only recently seen the company launch and land three Falcon 9 boosters in the space of 36 hours.
A research team has identified a molecular target that could open up new therapeutic options to treat aging-associated diseases like Parkinson’s. Scientists at the University of Cologne have discovered how cells can eliminate mutated mitochondrial DNA (mtDNA). Mitochondria are the powerhouses of our cells. Due to their evolutionary descent from bacteria, they still have genetic material packaged in chromosome-like structures (nucleoids). They convert the chemical energy in our food into a biologically usable form. A team of researchers from the University of Cologne’s Physiology Centre at the Faculty of Medicine, the Centre for Molecular Medicine Cologne (CMMC) and the CECAD Cluster of Excellence for Aging Research has now shown that mutations of the mtDNA lead to a local rearrangement of proteins in the mitochondrial membrane. The mutated mtDNA is targeted, eliminated, and subjected to autophagy, the cellular ‘waste disposal’. The results have appeared in Nature Communications under the title ‘Mitochondrial membrane proteins and VPS35 orchestrate selective removal of mtDNA’.
In many tissues, mutations in mtDNA accumulate as a result of normal aging. These kinds of mutations are an important cause of many aging-associated diseases. There are thousands of copies mtDNA in every cell, so mitochondrial function is only impaired when the percentage of mutated mtDNA molecules exceeds a certain threshold value. It has long been established that mitochondrial damage, including acute mtDNA damage, triggers the process of mitophagy. In this process, dysfunctional mitochondrial parts are selectively degraded and recycled.
Dr David Pla-Martin, the lead author of the current study, explained the details: ‘What is new in our study is that this mechanism does not affect the cells’ endowment with mitochondria, but only clears out the damaged mtDNA. By labelling neighbouring proteins — so-called proximity labelling — we showed that mtDNA damage leads to the recruitment of endosomes in close proximity to nucleoids.’ Their removal is coordinated by the interaction of the nucleoid protein Twinkle and the mitochondrial membrane proteins SAMM50 and ATAD3 controls their distribution, SAMM50 induces the release and transfer of the nucleoid to the so-called endosomes. ‘This additionally prevents the activation of an immune response. The protein VPS35, the main component of the retromer, mediates the maturation of early endosomes into late autophagy vesicles, where degradation and recycling ultimately take place,’ said Pla-Martin.
